Loading
Biomea Fusion, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Erdtmann Rainer M, was filed 15 Dec 2025.
Biomea Fusion, Inc.: what insiders have been doing
Every trade that managers of Biomea Fusion, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 23 October 2026, brought 4 filings signed by 2 insiders.
Not one open-market sale was filed. On the buying side, 2 insiders reported 4 purchases totalling €169k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 1 chief executive among the declarants. At €85k, the purchase published on 4 December 2025 by Hitchcock Michael J.M. is the largest of the period.
In the case of 2 purchases, another manager of the company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. The latest purchase dates back some time: it was published 313 days ago, on 15 December 2025. The median gap between a trade and its publication by SEC (Form 4) is 3 days. For comparison, the SEC allows two business days to file a Form 4.
Compared with its exchange (3,167 companies, median 24 filings), a count of 4 filings is below the norm. Looking back to 2021, when coverage begins, insiders filed 19 purchases and 9 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of -61.8 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
56
Thresholds
n/a
Buy Volume
€28M
19 ops. · all time
Sell Volume
€24M
9 ops. · all time
Who traded when
BuySaleRainer M. Erdtmann3 buys
Michael J.M. Hitchcock1 buy
Since the insiders bought
- -8.8%Entry US$1.37 · Close at T+90 US$1.25
- +12.3%Entry US$1.22 · Close at T+90 US$1.37
- -59.4%Entry US$5.81 · Close at T+365 US$2.36
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Biomea Fusion, Inc. Buy (bullish), based on 6 analysts. Average price target: US$6.17.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.87
Analyst consensus
6 analystsBuy
US$4.00Target US$6.17(+610%)US$10.00
Income statement
EBITDA-US$79.9M
Net income-US$61.8M0.0% margin
Valuation
PER (forward)-0.9x
P/Book5.2x
Beta-0.30
Balance sheet & cash
Market capUS$63M
Total debtUS$1.6M
Free Cash Flow-US$70.4M
Debt / Equity7%
Profitability & ownership
ROE-164.1%
ROA-63.5%
% insiders7.1%
% institutions40.0%
Last declaration on 15 December 2025
Declarations56 total
30,000 shares@ US$1.43331.3% of flowCommon StockSEC:0001193125-25-319222:0
Canonical exit: 11 Mar 2026 (T+90)
100,000 shares@ US$0.991839.9% of flowCommon StockSEC:0001193125-25-308091:0
Canonical exit: 2 Mar 2026 (T+90)
10,000 shares@ US$1.052.6% of flowCommon StockSEC:0001193125-25-305287:1
Canonical exit: 1 Mar 2026 (T+90)
40,000 shares@ US$1.10131.3% of flowCommon StockSEC:0001193125-25-305287:0
Canonical exit: 26 Feb 2026 (T+90)
10,000 shares0Common StockSEC:0000950170-25-108041:1
10,000 shares0Common StockSEC:0000950170-25-108041:2
10,000 shares0Common StockSEC:0000950170-25-108041:3
10,000 shares0Common StockSEC:0000950170-25-108041:4
10,000 shares0Common StockSEC:0000950170-25-108041:5
10,000 shares0Common StockSEC:0000950170-25-108041:6
40,000 shares0Common StockSEC:0000950170-25-108041:0
495 shares@ US$6.1541.7% of flowCommon StockSEC:0000950170-24-132253:0
10,000 shares@ US$10.0642.2% of flowCommon StockSEC:0000950170-24-110858:0
Canonical exit: 29 Dec 2024 (T+90)
12,509 shares@ US$4.4323.5% of flowCommon StockSEC:0000950170-24-072494:1
Canonical exit: 9 Sept 2024 (T+90)
4,448 shares@ US$3.78259.2% of flowCommon StockSEC:0000950170-24-072494:0
349 shares@ US$8.942100.0% of flowCommon StockSEC:0000950170-24-072493:0
3,000 shares0Common StockSEC:0000950170-24-000956:1
3,000 shares0Common StockSEC:0000950170-24-000956:2
3,000 shares0Common StockSEC:0000950170-24-000956:3
3,000 shares0Common StockSEC:0000950170-24-000956:4
3,000 shares0Common StockSEC:0000950170-24-000956:5
12,000 shares0Common StockSEC:0000950170-24-000956:6
3,000 shares0Common StockSEC:0000950170-24-000956:0
1,345 shares@ US$3.78252.8% of flowCommon StockSEC:0000950170-23-067424:0
50,000 shares@ US$34.56Common StockSEC:0001859061-23-000007:1
25 of 56 declarations
About Biomea Fusion, Inc.
Biomea Fusion, Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq market in the United States under the ticker BMEA. The company is focused on metabolic health, with a strategic emphasis on diabetes and obesity. It was founded in August 2017 as a Delaware entity and has since sharpened its corporate identity from a broader biotech profile into a more focused clinical-stage metabolic medicines company. Biomea is headquartered in San Carlos, California, in the San Francisco Bay Area biotech corridor. ([investors.biomeafusion.com](https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-enters-2026-focused-executing-key-icovamenib-and?utm_source=openai))
Biomea’s current business is built around two lead oral clinical programs: icovamenib and BMF-650. Icovamenib is described by the company as a potentially first-in-class covalent menin inhibitor being developed for diabetes, including type 2 diabetes patients who are not adequately controlled on standard-of-care therapies, such as GLP-1-based treatments. BMF-650 is a next-generation oral GLP-1 receptor agonist candidate designed for obesity and broader metabolic disease applications. The company’s emphasis on oral therapies is strategically important, because it aims to address a major market need: combining meaningful metabolic efficacy with a more convenient dosing route than the injectable treatments that dominate much of the category today. ([investors.biomeafusion.com](https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-enters-2026-focused-executing-key-icovamenib-and?utm_source=openai))
Read moreShow less
From a competitive standpoint, Biomea remains a clinical-stage, pre-revenue biotech company, which means the investment case is highly dependent on clinical readouts, tolerability, regulatory progress, and funding execution. That said, the company’s positioning is differentiated. Rather than competing only as another diabetes or obesity entrant, Biomea is trying to serve patient subsets that remain underserved by the current standard of care, while simultaneously extending its metabolic platform into obesity through BMF-650. This gives the company exposure to two large and highly competitive therapeutic markets, but with a narrative centered on oral convenience and potential disease-modifying impact if the data continue to validate the mechanism. ([investors.biomeafusion.com](https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-enters-2026-focused-executing-key-icovamenib-and/?utm_source=openai))
Recent developments have been centered on clinical execution. In 2026, Biomea announced the first patient dosed in its newly initiated Phase II programs, COVALENT-211 and COVALENT-212, for icovamenib in type 2 diabetes. The company also said it is advancing BMF-650, with 28-day weight-loss data expected in the first half of 2026 from a Phase I obesity study. In parallel, Biomea has continued to present data and corporate updates at scientific conferences and has highlighted a capital structure intended to fund key clinical milestones into 2027. For French-speaking investors, BMEA is therefore best viewed as a high-risk, high-upside Nasdaq biotech story in the United States, with value creation hinging on the next set of clinical data and the company’s ability to translate promising biology into registrable assets. ([investors.biomeafusion.com](https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-announces-first-patient-dosed-newly-initiated?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
